Skip to Main Content




Infections with helminths, or parasitic worms, affect more than two billion people worldwide. In regions of rural poverty in the tropics, where prevalence is greatest, simultaneous infection with more than one type of helminth is common. The relative incidence of common helminthic infections in humans worldwide is illustrated in Figure 51–1.

Figure 51–1.

Relative incidence of helminth infections worldwide.

Graphic Jump Location

Worms pathogenic for humans are Metazoa and can be classified into roundworms (nematodes) and two types of flatworms, flukes (trematodes) and tapeworms (cestodes). These biologically diverse eukaryotes vary with respect to life cycle, bodily structure, development, physiology, localization within the host, and susceptibility to chemotherapy. Immature forms invade humans via the skin or GI tract and evolve into well-differentiated adult worms with characteristic tissue distributions. With few exceptions, such as Strongyloides and Echinococcus, these organisms cannot complete their life cycle and replicate within the human host to produce mature offspring. Therefore, the extent of exposure to these parasites dictates the number of parasites infecting the host, a characteristic recognized as infection intensity, which itself determines the morbidity caused by infection. Secondly, any reduction in the number of adult organisms by chemotherapy is sustained unless reinfection occurs. The burden of parasitic helminths within an infected population is not uniformly distributed, and it typically displays a negative binomial distribution whereby relatively few persons carry the heaviest parasite burden, resulting in increased morbidity in these individuals who also contribute disproportionately to transmission.


Anthelmintics are drugs that act either locally within the gut lumen to cause expulsion of worms from the GI tract, or systemically against helminths residing outside the GI tract. Safe and effective broad-spectrum anthelmintics, initially developed for veterinary use, are currently available for use in humans. However, therapy for many tissue-dwelling helminths, such as filarial parasites, is not fully effective. For many reasons, including their long-lived and relatively complex life cycles, acquired resistance to anthelmintics in humans has yet to become a major clinical problem. However, with the increasing deployment of mass drug therapy, and considering the veterinary experience with resistance, the potential for drug resistance among helminths in humans requires monitoring.


Primarily as a result of stepped-up advocacy by the World Health Organization (WHO), the World Bank, the Global Network for Neglected Tropical Diseases, and smaller nongovernmental organizations such as the London-based Partnership for Child Development (PCD), there is increasing appreciation for the impact of helminth infections on the health and education of school-aged children. These organizations have promoted the periodic and frequent use of anthelmintic drugs in schools as a means to control morbidity caused by soil-transmitted helminths and schistosomes in developing countries. In addition, interest has grown in eliminating arthropod-borne helminth infections by interrupting their transmission through the widespread use of anthelmintics. Today, control programs employing anthelmintics rank among the world's largest health efforts, ...

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.


Create a Free MyAccess Profile

* Required Fields

Note: If you have registered for a MyAccess profile on any of the Access sites, you can use the same MyAccess login credentials across all sites.

Passwords must be between 6 and 40 characters long (no whitespace), cannot contain characters #, &, and must contain:
  • at least one lowercase letter
  • at least one uppercase letter
  • at least one digit

Benefits of a MyAccess Profile:

  • Remote access to the site off-campus on any device
  • Notification of new content via custom alerts
  • Bookmark your favorite content such as chapters, figures, tables, videos, cases and more
  • Save and download images to PowerPoint
  • Self-Assessment quizzes saved for quick review
  • Custom Curriculum access for both instructors and learners

Subscription Options

AccessAnesthesiology Full Site: One-Year Subscription

Connect to the full suite of AccessAnesthesiology content and resources including procedural videos, interactive self-assessment, real-life cases, 20+ textbooks, and more

$995 USD
Buy Now

Pay Per View: Timed Access to all of AccessAnesthesiology

24 Hour Subscription $34.95

Buy Now

48 Hour Subscription $54.95

Buy Now

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.